Organization (Industry)
PERRIGO COMPANY
ClinicalTrials.gov lists PERRIGO COMPANY as lead sponsor of 18 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Perrigo Company plc, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers PERRIGO COMPANY and 3 companies grouped under it: 18 lead-sponsored trials (7 its own, 11 in the grouped companies) and 12 legal-entity registrations (11 its own, 1 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Laboratoire de la Mer | 6 | 1 |
| ACO Hud Nordic AB | 4 | 0 |
| PBM Nutritionals | 1 | 0 |
Disease areas (6)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Bone Diseases, Metabolic | 1 |
| Breast Neoplasms | 1 |
| COVID-19 | 1 |
| Common Cold | 1 |
| Cough | 1 |
Showing 5 of 6 disease areas.
Trials by start year as sponsor or collaborator (6)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2019 | 1 |
| 2012 | 1 |
| 2010 | 1 |
| 2004 | 5 |
| 2003 | 1 |
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pediatrics | 2 |
| American journal of public health | 1 |
| International journal of surgery (London, England) | 1 |
| Journal of nutrition education | 1 |
| Journal of nutrition education and behavior | 1 |
Showing 5 of 7 journals.
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 4,253,100,000 | -1,425,400,000 | 95,400,000 |
| 2024 | 4,373,400,000 | -171,800,000 | 112,200,000 |
| 2023 | 4,655,600,000 | -12,700,000 | 122,500,000 |
| 2022 | 4,451,600,000 | -140,600,000 | 123,100,000 |
| 2021 | 4,138,700,000 | -68,900,000 | 122,000,000 |
| 2020 | 4,088,200,000 | -162,600,000 | 121,700,000 |
| 2019 | 3,869,900,000 | 146,100,000 | 119,200,000 |
| 2018 | 4,731,700,000 | 131,000,000 | 218,600,000 |
| 2017 | 4,946,200,000 | 119,600,000 | 167,700,000 |
| 2016 | 5,280,600,000 | -4,012,800,000 | 184,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (33)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-30 | Other financing | not disclosed | Sec extracted |
| 2026-04-30 | Other financing | not disclosed | Sec extracted |
| 2026-03-20 | Debt financing | not disclosed | Sec extracted |
| 2026-03-20 | Debt financing | not disclosed | Sec extracted |
| 2025-07-14 | Other financing | not disclosed | Sec extracted |
Showing 5 of 33 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2040 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (43)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-20 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-20 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-14 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 43 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP19A1 | Trial collaborator | Named in trial inclusion criteria |
| ESR1 | Trial collaborator | Named in trial inclusion criteria |
| CYP19A1 | Trial collaborator | Mentioned in trial text |
| ESR1 | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.